Qiagen N.V. (NYSE:QGEN) Stock Has Average Target Price of $46.34 According to Brokerages

Shares of Qiagen N.V. (NYSE:QGEN) have been given an average rating of “Hold” by the fifteen brokerages that are currently covering the company, MarketBeat Ratings reports. Eleven research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $46.34.

Several equities research analysts have recently commented on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. Citigroup restated a “neutral” rating and issued a $52.00 price objective (up from $45.00) on shares of Qiagen in a report on Monday, October 26th. JPMorgan Chase & Co. cut shares of Qiagen from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $55.00 to $52.00 in a research note on Thursday, October 22nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Finally, Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a report on Friday, August 7th.

Qiagen Price Performance

NYSE QGEN traded down $0.18 during trading hours on Friday, reaching $49.92. 1,642,137 shares of the company’s stock were exchanged, compared to its average volume of 6,745,182. The firm has a fifty day moving average of $46.51 and a 200-day moving average of $42.65. Qiagen has a one year low of $32.53 and a one year high of $57.81. The stock has a market cap of $10.29 billion, a PE ratio of 27.28, a price-to-earnings-growth ratio of 4.01 and a beta of 0.56. The company has a current ratio of 2.63, a quick ratio of 2.31 and a debt-to-equity ratio of 0.43.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Qiagen had a net margin of 18.19% and a return on equity of 14.70%. The firm had revenue of $547.87 million for the quarter, compared to analyst estimates of $538.61 million. During the same quarter in the prior year, the firm earned $0.61 EPS. The company’s revenue was up 2.8% on a year-over-year basis. On average, equities research analysts predict that Qiagen will post 2.44 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Large investors have recently made changes to their positions in the company. First Command Advisory Services Inc. grew its stake in shares of Qiagen by 2,190.0% during the 3rd quarter. First Command Advisory Services Inc. now owns 916 shares of the company’s stock worth $40,000 after acquiring an additional 876 shares in the last quarter. Hilltop National Bank bought a new stake in shares of Qiagen in the second quarter worth $50,000. Integrated Wealth Concepts LLC bought a new stake in shares of Qiagen in the second quarter worth $59,000. Allworth Financial LP boosted its holdings in Qiagen by 20.8% during the second quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after purchasing an additional 317 shares during the last quarter. Finally, denkapparat Operations GmbH acquired a new position in Qiagen during the second quarter worth $105,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.